Intranasal administration
US10112021B2 · kind B2 · utility
2Cited by
56References
34Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 2, 2015 |
| Grant date | Oct 30, 2018 |
| Priority date | — |
| Expiry date | Mar 2, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2210/0625
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.